Erratum
Open Access
Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
Received: 21 December 2015
Accepted: 21 December 2015
Published: 11 January 2016
The original article was published in BMC Cancer 2015 15:941
Unfortunately, the original version of this article [1] contained a mistake. The word ‘survivin’ in the title was incorrectly included as ‘surviving’. The title has been corrected above and in the original article.
Notes
Declarations
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
(1)
Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila
(2)
Pathology Division, San, Salvatore Hospital
(3)
Karyopharm Therapeutics
Reference
- Gravina G, Mancini A, Sanita P, Vitale F, Marampon F, Ventura L. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models. BMC Cancer. 2015;15:941.View ArticlePubMedPubMed CentralGoogle Scholar
Copyright
© Gravina et al. 2016
